ENLIVEX THERAPEUTICS LTD ENLV 深 沪
等待开盘 10-24 09:30:00 美东时间
1.055
-0.005
-0.47%
华盛通- 最 高1.065
- 今 开1.06
- 成交量 7.51万股
- 最 低 1.04
- 昨 收 1.06
- 总市值 2517.05万
- 52周最高 2.10
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 0.8101
- 委 比 71.83%
- 总股本 2385.83万
- 历史最高 44.90
- 量 比 0.57
- 振 幅 2.36%
- 历史最低 0.8101
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Enlivex Therapeutics will participate in a webinar on September 30, 2025, discussing breakthroughs in knee osteoarthritis treatment. The webinar, hosted by D. Boral Capital, will feature leading experts and discuss positive Phase IIa data from Enlivex's Allocetra™ program, showing significant pain reduction and functional improvement in patients.
09-29 12:15
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.
09-12 20:00
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Enlivex Therapeutics Ltd. reported promising Phase IIa results for Allocetra™ in knee osteoarthritis (KOA), showing significant pain reduction and functional improvement in older patients. The treatment was well-tolerated, with no serious adverse events. Key findings included a 72% reduction in pain and 109% improvement in function compared to placebo. Enlivex plans to release six-month data by November 2025 and initiate a Phase IIb trial in Q2 2...
09-11 12:00
Enlivex Secures Israeli Patent For Allocetra In Osteoarthritis Treatment, Extending IP Protection Through 2040
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, "THERAPEUTIC
09-09 20:03
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
<p>Enlivex Therapeutics Ltd. has been granted an Israeli patent for using Allocetra™ to treat osteoarthritis, providing protection through at least 2040. The company reported positive Phase IIa data showing 24% knee pain reduction and 26% improvement in knee function with Allocetra™. CEO Oren Hershkovitz expressed confidence in securing similar patents globally. Osteoarthritis affects millions and has no approved treatments to slow joint damage, ...
09-09 12:00
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7 price target.
09-02 19:16
Enlivex’s Allocetra: A New Hope for Psoriatic Arthritis?
Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical st...
08-21 00:16
Enlivex to Present Key Results from Osteoarthritis Trial
An update from Enlivex ( ($ENLV) ) is now available. On August 14, 2025, Enlive...
08-14 20:57
Enlivex To Present 3-Month Topline Data From Phase IIa Stage Of Its Phase I/IIa ENLX-CL-05-001 Trial
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis
08-14 20:43
